Zelboraf

GPTKB entity

Statements (46)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:FDA
gptkbp:atccode L01 XE30
gptkbp:availability prescription only
gptkbp:brand gptkb:Zelboraf
gptkbp:chemical_formula C23 H22 Cl F2 N3 O2 S
gptkbp:class antineoplastic agent
gptkbp:clinical_trial gptkb:BRIM-2
gptkb:BRIM-3
Phase III
BRIM-1
gptkbp:contraindication hypersensitivity to vemurafenib
gptkbp:dosage_form gptkb:tablet
gptkbp:drug_interactions CYP450 inducers
CYP450 inhibitors
gptkbp:excretion urine
feces
https://www.w3.org/2000/01/rdf-schema#label Zelboraf
gptkbp:indication gptkb:BRAF_V600_E_mutation-positive_melanoma
gptkbp:ingredients gptkb:vemurafenib
gptkbp:manufacturer gptkb:Genentech
gptkbp:market ongoing
gptkbp:marketed_as gptkb:2011
gptkbp:mechanism_of_action BRAF inhibitor
gptkbp:patient_population adults
gptkbp:pharmacokinetics metabolized by liver
bioavailability 100% (oral)
half-life 57 hours
gptkbp:previous_name gptkb:vemurafenib
gptkbp:price high
gptkbp:route_of_administration oral
gptkbp:safety_measures photosensitivity
skin cancer risk
hepatotoxicity
QT prolongation
ocular toxicity
gptkbp:side_effect fatigue
nausea
rash
joint pain
itching
gptkbp:storage room temperature
gptkbp:type_of_care important for efficacy
gptkbp:used_for treatment of melanoma
gptkbp:bfsParent gptkb:Merck_Serono
gptkbp:bfsLayer 5